What does pharma look for in evaluating companies as potential partners?

Declan Jones, PhD
VP, Neuroscience Lead, J&J Innovation Centre, London

Alzheimer's Association Business Consortia Webinair, Feb 24th 2016
Notice Regarding Forward-Looking Statements

This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities regarding approval, labeling and other matters that could affect the availability or commercial potential of product candidates; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; challenges to patents; the impact of patent expirations; impact of business combinations and divestitures; competition, including technological advances, new products and patents attained by competitors; future clinical data and analysis, including post marketing surveillance; economic factors, such as interest rate and currency exchange rate fluctuations; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in these presentations speak only as of the date of these presentations. The Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.
What does pharma look for in evaluating companies as potential partners?

Agenda

- Neuroscience research at Janssen Research & Development
- What are the challenges in drug discovery in Alzheimer’s Disease?
- What are the most pressing needs for Pharma?
- Introduction to J&J Innovation
- Key questions for drug discoverers
- Examples of our partnerships
Janssen R&D Leading the Way in Next Neuroscience Frontier

- Leveraging scientific advances in neural plasticity, cellular resilience
- Building on strategic advantages, internal expertise and strong external networks
- Advancing methodologies in clinical trials, biomarkers, translational medicine
- Moving earlier into disease processes from diagnose and treat to predict and preempt

SCHIZOPHRENIA  MOOD DISORDERS
CHRONIC PAIN   ALZHEIMER’S DISEASE
## Janssen R&D Neuroscience Portfolio (as of May 2015)

<table>
<thead>
<tr>
<th>APPROVED PRODUCTS</th>
<th>PLANNED FILINGS 2015-2019</th>
<th>SELECTED EARLY TO MID STAGE PIPELINE²</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PLANNED FILINGS</strong></td>
<td></td>
<td><strong>Alzheimer’s Disease</strong></td>
</tr>
<tr>
<td><strong>Paliperidone palmitate</strong></td>
<td>- 3-month long-acting injectable (EU)</td>
<td>- Lead BACE Inhibitor: Alzheimer’s dementia in asymptomatic individuals</td>
</tr>
</tbody>
</table>
| **Esketamine (intranasal)** | - Treatment-resistant depression  
- Major Depressive Disorder at imminent risk for suicide | - BACE Inhibitor back up |
| **Fulranumab** | - Osteoarthritis pain | - Anti-Tau vaccine: prodromal Alzheimer’s disease |
| **JNJ-922 (Orexin-2 antagonist)** | - Primary insomnia | - AAB-003: prodromal Alzheimer’s disease |
| **Point-of-care diagnostic¹** | - Schizophrenia | - Alpha-2C AR antagonist: neurobehavioral symptoms in Alzheimer’s disease |

**Mood Disorders**
- JNJ-922 (Orexin-2 antagonist): adjunctive major depressive disorder
- Sirukumab: major depressive disorder
- Orexin-1 antagonist: mood disorders
- P2X7 antagonist: mood disorders
- FAAH inhibitor: anxious depression

1. 510(k) filing in US and CE Mark in EU planned.
2. Filings expected beyond 2019. This information is accurate as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.

Note: Filings/approvals assumed to be in US, EU unless otherwise noted.
Alzheimer’s Disease
Tackling the Complex Interconnected Pathology on Multiple Fronts

- BACE Inhibition
- Amyloid Immunotherapy (N-terminal mAbs)
- Anti-Tau Vaccine
- Preventing synaptic dysfunction?
Alzheimer’s Disease Non-invasive Diagnostics
Enable Early Detection of Alzheimer’s Pathology in the Community

Eye Gaze Tests for Cognition
Retinal Amyloid
Computerized Verbal Memory Tests
Blood-based Markers
mRNA, micro RNA, proteomics
Metabolomics
Antibody arrays
CNS Drug Discovery – Little risk discharge before Phase 2!

Right target, right patient, right tissue, right safety, right commercial value?

(Nat Rev Drug Disc, 2014, 13, 419-431)

- This is a team sport
- Output is binary!

Cumulative Probability of Success

Least investment in Pharma R&D

Highest incremental risk at POC stage

1.0

Cumulative Cost

0

0.5

12+

Years

LO stage^2

TI/TV^2

Pre-Clinical

Phase I

Phase IIa

Phase IIb

Phase III

FDA Review

1 CMR benchmarks used to calculate risk-adjusted values at various stages, 2 Internal
The most pressing needs for Pharma?

Right target, right patient, right tissue, right safety, right commercial value


- Tool generation for TI/TV?
- Novel treatment modalities?
- More predictive models

Access to well characterized subject or patient cohorts

Target engagement & pharmacology translation?

More efficient methods to predict for efficacy

Diagnostics, Biomarkers of disease risk, progression, & treatment response etc

**Biggest win?**
Reduce the cost & complexity of clinical trials to expand clinical experimentation
What is defeat? Nothing but education; nothing but the first steps to something better.

- Proverb

The secret is to gang up on the problem, rather than each other.

- Thomas Stallkamp
External drug discovery is not new - Origin of medicines in the EU (2010-12)

“...SMEs...academia, public bodies & PPPs represent an important source of innovation.”

Integrated Internal and External R&D model

- External Discovery Engines
- External TI/TV
- Neuroscience Internal R&D
- Incubators, Spin-outs etc
- Strategic L&A/M&A
- Public-private Partnerships

Logos and branding from various organizations, including Johnson & Johnson Innovation, EMIF, NIH, and others.
Neuroscience Leads:
Jeff Nye, Head & Boston
Guy Seabrook - CA
Declan Jones - London
Eric Schaeffer - NJ, Boston

- Janssen Business Development
- Our Corporate VC – J&J Development Corporation
- Our Incubator - JLABS  http://jlabs.jnjinnovation.com/
J&J Innovation - What We Consider & How We Prioritize

- Conviction level of experts in science & target
- Ability to establish pre-clinical and clinical POC
- Time and cost to preclinical and clinical POC
- Leadership potential (competitive landscape)
- Strategic fit for J&J
- IP strength
- Collaboration capability of partner
- Patient impact (medical need)
- Societal impact (e.g. patient years)
- Transformative potential at time of launch
- Cost of access (deal terms)
Key questions for drug discoverers

• What problem will this solve?
  – What standard of care will this displace in 10-15 years time?

• What is the strategy for discovery & development?
  – Is it a druggable target?
  – How far along the path can you take this (Exit?)?
  – Do you have the right support network?
  – Are there killer experiments and Go/No Go points?
  – When are the major risks discharged?

• What do you “own” and what do you want to control?

• How does a partnership mesh with your company’s overall strategy?

• What are you looking for from a partner?
Example partnerships: Therapeutics in AD

Alector Teams Up with Johnson & Johnson Innovation to Explore Novel Alzheimer’s Target

By Alector In Johnson & Johnson, Partnerships

SAN FRANCISCO – March 10, 2014 – Alector, LLC announced today a collaborative research agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Janssen Pharmaceuticals, Inc. will fund research in one of Alector’s targets through proof-of-concept disease models and will retain a time-limited option to negotiate a commercial agreement.

Alector is located at Janssen Labs @QB3 in San Francisco. Through a collaboration with QB3, Janssen Labs @QB3 aims to provide a capital efficient, flexible model for external companies pursuing important healthcare innovations. It features a no-strings attached approach which is a key component of the flagship Janssen Labs in San Diego.
Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies

* Collaborative effort will explore genes dysregulated in Alzheimer's disease patients to identify new targets for drug discovery and development

Hamburg, Germany - 08 November 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN:

Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease

Hamburg, Germany - 12 January 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN:

Cypralis Limited announces collaboration with Johnson & Johnson Innovation in the field of neurodegenerative diseases

7th December 2015

Ongar, UK, 7th December 2015 / Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerase (PPIases), has entered into a collaboration with Janssen Pharmaceuticals I
Example partnerships – Diagnostics in AD

DiamiR Announces Research Collaboration With Johnson & Johnson Innovation

MONMOUTH JUNCTION, NJ--(Marketwired - January 11, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson Innovation facilitated the agreement.

DiamiR has developed a proprietary targeted approach for early detection and monitoring of neurodegenerative diseases based on quantitative analysis of brain-enriched microRNA pairs in plasma. In this collaboration, DiamiR and Janssen Neuroscience teams will jointly investigate how DiamiR technology can be used in the context of clinical development of a therapeutic agent for treatment of neurodegenerative disease indications.

NeuroVision Expands Collaboration with Janssen Research & Development, LLC to Advance Alzheimer’s Research

SACRAMENTO, Calif. (Feb. 10, 2016) - NeuroVision Imaging LLC has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration. The collaboration will enable NeuroVision to further validate its retinal imaging technology and develop its technology for potential early detection and monitoring of amyloid pathology related to Alzheimer’s disease. The collaboration is intended to help NeuroVision further develop the foundation for wide, global adoption of its technology, including participation in Janssen clinical trials.
Novel Partnerships - Incubators

- FutuRx - leverages the dynamic scientific environment in Israel
  - Combines the attributes of VC, Pharma, Academia, local management
  - Vast experience in company start-ups, drug development know-how in multiple diseases & technologies

- JLABS provides a 'no strings attached' access to incubator facility
  - Space & equipment
  - Educational and nurturing program
  - Currently SF, La Jolla, Boston, Houston, Toronto

http://jlabs.jnjinnovation.com/
De-risking early science – identify biomarkers, repurpose clinical assets?

• Neuroinflammation in Mood & Alzheimer’s (NIMA) consortium

• Builds upon existing projects (e.g., EMIF) to investigate NI in AD
  • Bioinfomatics, epidemiology, preclinical, and clinical projects
  • Identify biomarkers, select patients, reposition drugs etc
Dementias Platform UK – improving experimental medicine in AD

- Consortium of UK Academics, SME, & Pharma partners (> $85M funding)
- Provides platform and infrastructure for dementia research
  - Deliver informatics, biomarkers, cohorts & subjects (EPAD), experimental medicine studies

![Diagram](image)
PPP to re-position novel clinical assets

“Discovering New Therapeutic Uses for Clinical Stage Molecules”
- Probe potential new indications for novel targets
- De-risk novel mechanisms to drive further discovery investments
- Co-funded model - clinical supply from industry, study funding from NIH

“Development of a novel therapeutic for smoking cessation”

Academic Partners: Darlene H. Brunzell, Ph.D., Virginia Commonwealth University, Richmond and Kenneth Alan Perkins, Ph.D., University of Pittsburgh

Industry Partner: Janssen Research & Development, LLC

ECNP Medicines Chest
*Some sources of funding for dementia drug discovery.....

*far from exhaustive list
Thank you

DJone119@its.jnj.com

www.jnjinnovation.com